POTASSIUM CHLORIDE 20MEQ
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ (POTASSIUM CHLORIDE 20MEQ).
Potassium is the primary intracellular cation essential for maintaining cell membrane potential, nerve impulse transmission, muscle contraction, and acid-base balance. Potassium chloride supplementation corrects hypokalemia and prevents potassium depletion.
| Metabolism | Potassium is not metabolized; it is primarily excreted by the kidneys (90%) with small amounts lost in feces and sweat. |
| Excretion | Renal: >90% (primarily as potassium ions), Fecal: <10% (unabsorbed) |
| Half-life | Terminal elimination half-life is approximately 5-6 hours; clinical context: varies with renal function and potassium loads |
| Protein binding | Approximately 0-10% (minimally bound; no specific binding proteins) |
| Volume of Distribution | Approximately 0.5-1.0 L/kg (distributes primarily in extracellular fluid with gradual intracellular uptake) |
| Bioavailability | Oral: 80-100% (absorption nearly complete, minimal first-pass metabolism) |
| Onset of Action | Oral: 30-60 minutes; Intravenous: immediate (within minutes) for serum potassium increase |
| Duration of Action | Oral: effect lasts 2-4 hours for serum potassium elevation; IV: effect lasts 1-2 hours post-infusion; clinical notes: duration depends on renal function and total body potassium stores |
| Molecular Weight | 74.55 |
Oral: 20 mEq (one tablet or packet) once or twice daily, with or after meals; maximum 40 mEq per dose and 100 mEq per day. Intravenous: 10-20 mEq/hour, not exceeding 20 mEq/hour or 200 mEq/day; central line administration preferred for concentrations >40 mEq/L.
| Dosage form | INJECTABLE |
| Renal impairment | GFR ≥60 mL/min: no adjustment. GFR 30-59: use with caution, reduce dose by 25-50%. GFR <30: avoid use due to risk of hyperkalemia. |
| Liver impairment | No specific dose adjustment recommended. Monitor potassium levels closely in patients with severe hepatic impairment due to potential for acid-base disturbances. |
| Pediatric use | Neonates and infants: 1-2 mEq/kg/day divided. Children: 1-3 mEq/kg/day divided, not to exceed 1 mEq/kg/hour IV or 40 mEq/dose. Adjust based on serum potassium. |
| Geriatric use | Start at lower end of dosing range (10-20 mEq/day oral) due to age-related decline in renal function. Monitor potassium and renal function frequently. |
| 1st trimester | Potassium chloride is essential for cellular function. No teratogenic effects reported at physiological doses. Use only if clearly needed to correct hypokalemia. |
| 2nd trimester | Potassium chloride is essential for maternal and fetal health. Monitor serum potassium closely to avoid hyperkalemia, which can cause fetal arrhythmias. |
| 3rd trimester | Use with caution; hyperkalemia may lead to fetal bradycardia or arrhythmias. Avoid in preeclampsia or renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ (POTASSIUM CHLORIDE 20MEQ).
| Placental transfer | Potassium readily crosses the placenta via active transport. Fetal serum levels are typically similar to maternal levels. Excessive maternal doses can cause fetal hyperkalemia. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Administration of potassium chloride at therapeutic doses is considered compatible with breastfeeding. Monitor infant for hyperkalemia symptoms if maternal doses are excessive. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is not teratogenic. Normal maternal potassium levels are essential for fetal development; both hypokalemia and hyperkalemia can cause adverse fetal outcomes. No increased risk of congenital anomalies with therapeutic use. |
| Fetal Monitoring | Monitor serum potassium levels, renal function, and ECG in pregnancy. Assess for signs of hyperkalemia. Fetal monitoring may include ultrasound for growth and amniotic fluid assessment if maternal potassium disturbances occur. |
| Fertility Effects | No known adverse effects on fertility. Potassium balance is important for reproductive function; severe disturbances may affect ovulation or spermatogenesis. |
■ FDA Black Box Warning
Potassium chloride injections concentrate (≥2 mEq/mL) must be diluted before use to avoid fatal hyperkalemia. Accidental administration of undiluted concentrate can cause cardiac arrest.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaConcurrent use with potassium-sparing diureticsMetabolic acidosisCockcroft-Gault GFR less than 30 mL/min
| Precautions | Hyperkalemia risk, especially in renal impairment, rapid IV administration, or with potassium-sparing diuretics, Cardiac monitoring required during IV infusion, GI ulceration or perforation with oral solid dosage forms (use liquid or powder if GI stasis), Use caution in patients with cardiac disease, renal impairment, or acid-base disorders, ECG changes may precede hyperkalemia |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach, avocados, tomatoes, dried fruits, salt substitutes) when on high-dose potassium therapy. Alcohol may increase potassium loss. Grapefruit juice does not interact significantly. |
| Clinical Pearls | Potassium chloride 20 mEq is typically administered intravenously at a maximum rate of 10 mEq/hour via central line; peripheral administration should not exceed 10 mEq in 100 mL and rate of 5 mEq/hour to avoid phlebitis. Always confirm renal function before administration. ECG monitoring is essential during infusion for signs of hyperkalemia (peaked T waves, widened QRS). Contraindicated in severe renal impairment, untreated Addison's disease, and hyperkalemia. |
| Patient Advice | Take potassium supplements with food or a full glass of water to reduce stomach upset. · Do not crush or chew extended-release tablets; swallow whole. · Report symptoms of hyperkalemia: muscle weakness, fatigue, tingling in hands/feet, irregular heartbeat. · Avoid salt substitutes containing potassium unless directed by your doctor. · Do not stop taking without consulting your healthcare provider. |
Loading safety data…